Literature DB >> 8261304

Uraemia with concomitant urothelial cancer.

B P Jiaan1, C C Yu, Y H Lee, J K Huang.   

Abstract

We report our experience with 3 uraemic patients who were found to have transitional cell carcinoma of the renal pelvis, ureter and urinary bladder after undergoing haemodialysis for an average of 18 months (range 11-28). The underlying causes of renal failure were chronic glomerulonephritis or pyelonephritis. Bloody urethral discharge was the cardinal symptom. Because of anuria, it was often discovered at a late stage. In spite of their poor general condition and advanced stage, palliative surgical intervention was still performed. After a mean follow-up of 9 months, progression of disease was noted in 1 patient. The importance of regular follow-up in patients with end-stage renal disease for early detection of concomitant cancer cannot be over-emphasised. Uraemic patients with urothelial cancer should be treated in the same way as non-uraemic patients, since aggressive surgical intervention may improve their quality of life and prolong their survival.

Entities:  

Mesh:

Year:  1993        PMID: 8261304     DOI: 10.1111/j.1464-410x.1993.tb16177.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

1.  Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma.

Authors:  Shu-Fen Tseng; Yao-Chi Chuang; Wen-Chou Yang
Journal:  Int Urol Nephrol       Date:  2011-04-24       Impact factor: 2.370

2.  Simultaneous Cystectomy and Nephroureterectomy due to Synchronous Upper Urinary Tract Tumors and Invasive Bladder Cancer: Open and Laparoscopic Approaches.

Authors:  Manuel Pérez-Utrilla Pérez; Alfredo Aguilera Bazán; José M Alonso Dorrego; Rebeca Vitón Herrero; Jesús Cisneros Ledo; Javier de la Peña Barthel
Journal:  Curr Urol       Date:  2012-09-27

3.  A modified single mini-incision complete urinary tract exenteration for urothelial carcinoma in dialysis patients.

Authors:  I-Hsuan Chen; Jen-Tai Lin; Jeng-Yu Tsai; Tony Wu; Chia-Cheng Yu
Journal:  Biomed Res Int       Date:  2014-08-11       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.